Nifty
:
23587.50
Sensex
:
78041.59
-364.20 (-1.52%)
-1176.46 (-1.49%)
Nifty
Sensex
:
:
23587.50
78041.59
-364.20 (-1.52%)
-1176.46 (-1.49%)

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 533573 | NSE: APLLTD

NSE BSE
1055.15
20-Dec-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1047.80
  •  1081.90
  •  1046.50
  •  1047.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  304458
  •  3230.50
  •  1303.90
  •  746.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 20,737.41
  • 32.06
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 21,603.41
  • 1.04%
  • 4.24

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.61%
  • 0.18%
  • 7.35%
  • FII
  • DII
  • Others
  • 3.94%
  • 15.61%
  • 3.31%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.72
  • 6.22
  • 5.49

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.97
  • -5.14
  • 1.30

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.10
  • -5.77
  • 5.74

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.43
  • 26.17
  • 32.78

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.91
  • 3.49
  • 3.18

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.66
  • 16.14
  • 18.20

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
31.33
32.75
42.45
53.64
P/E Ratio
34.73
33.23
25.63
20.29
Revenue
6229
6708
7507
8350
EBITDA
933
1085
1340
1626
Net Income
616
645
835
1054
ROA
9.8
10.7
12.8
14.3
P/Bk Ratio
4.44
4.07
3.64
3.21
ROE
13.4
12.86
15.07
17.19
FCFF
429.98
475.63
646.25
750.43
FCFF Yield
1.96
2.16
2.94
3.41

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
1,647.98
1,594.93
3.33%
1,561.73
1,486.15
5.09%
1,516.98
1,406.45
7.86%
1,630.57
1,509.02
8.05%
Expenses
1,408.71
1,386.69
1.59%
1,324.90
1,287.45
2.91%
1,256.92
1,194.23
5.25%
1,364.21
1,260.26
8.25%
EBITDA
239.27
208.24
14.90%
236.83
198.70
19.19%
260.06
212.22
22.54%
266.36
248.76
7.08%
EBIDTM
14.52%
13.06%
15.16%
13.37%
17.14%
15.09%
16.34%
16.48%
Other Income
16.74
10.15
64.93%
2.10
11.66
-81.99%
3.59
0.89
303.37%
2.89
0.44
556.82%
Interest
18.81
15.69
19.89%
13.18
14.39
-8.41%
10.94
14.37
-23.87%
15.17
14.60
3.90%
Depreciation
70.51
67.56
4.37%
69.04
66.18
4.32%
69.48
74.12
-6.26%
69.45
66.51
4.42%
PBT
179.56
135.14
32.87%
156.71
129.79
20.74%
183.23
124.62
47.03%
184.63
168.09
9.84%
Tax
27.28
-1.93
-
22.49
9.16
145.52%
4.63
-36.43
-
4.13
32.57
-87.32%
PAT
152.28
137.07
11.10%
134.22
120.63
11.27%
178.60
161.05
10.90%
180.50
135.52
33.19%
PATM
9.24%
8.59%
8.59%
8.12%
11.77%
11.45%
11.07%
8.98%
EPS
7.81
6.95
12.37%
6.85
6.14
11.56%
9.07
7.76
16.88%
9.18
6.20
48.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
6,357.26
6,228.62
5,652.62
5,305.78
5,393.14
4,605.76
3,934.69
3,130.81
3,134.61
3,165.99
2,056.13
Net Sales Growth
6.02%
10.19%
6.54%
-1.62%
17.10%
17.06%
25.68%
-0.12%
-0.99%
53.98%
 
Cost Of Goods Sold
1,663.34
1,715.08
1,708.82
1,446.43
1,257.35
1,039.38
992.71
886.19
887.57
823.95
639.85
Gross Profit
4,693.92
4,513.54
3,943.80
3,859.35
4,135.79
3,566.38
2,941.98
2,244.62
2,247.04
2,342.04
1,416.28
GP Margin
73.84%
72.46%
69.77%
72.74%
76.69%
77.43%
74.77%
71.69%
71.68%
73.97%
68.88%
Total Expenditure
5,354.74
5,296.00
4,944.56
4,431.64
3,913.05
3,391.69
3,078.87
2,515.55
2,519.90
2,160.88
1,660.92
Power & Fuel Cost
-
173.37
151.54
120.84
118.72
102.40
88.86
70.35
64.20
58.89
43.31
% Of Sales
-
2.78%
2.68%
2.28%
2.20%
2.22%
2.26%
2.25%
2.05%
1.86%
2.11%
Employee Cost
-
1,446.29
1,169.13
1,133.00
1,051.17
906.44
746.69
622.81
558.83
472.85
306.76
% Of Sales
-
23.22%
20.68%
21.35%
19.49%
19.68%
18.98%
19.89%
17.83%
14.94%
14.92%
Manufacturing Exp.
-
387.71
409.37
379.15
372.18
368.41
269.25
244.53
289.79
271.51
263.38
% Of Sales
-
6.22%
7.24%
7.15%
6.90%
8.00%
6.84%
7.81%
9.24%
8.58%
12.81%
General & Admin Exp.
-
525.84
492.64
413.90
391.24
339.82
340.56
283.43
299.79
233.28
145.68
% Of Sales
-
8.44%
8.72%
7.80%
7.25%
7.38%
8.66%
9.05%
9.56%
7.37%
7.09%
Selling & Distn. Exp.
-
996.88
952.30
890.38
687.41
531.19
590.28
380.21
393.14
274.14
244.69
% Of Sales
-
16.00%
16.85%
16.78%
12.75%
11.53%
15.00%
12.14%
12.54%
8.66%
11.90%
Miscellaneous Exp.
-
50.83
60.76
47.94
34.98
104.05
50.52
28.03
26.58
26.26
244.69
% Of Sales
-
0.82%
1.07%
0.90%
0.65%
2.26%
1.28%
0.90%
0.85%
0.83%
0.84%
EBITDA
1,002.52
932.62
708.06
874.14
1,480.09
1,214.07
855.82
615.26
614.71
1,005.11
395.21
EBITDA Margin
15.77%
14.97%
12.53%
16.48%
27.44%
26.36%
21.75%
19.65%
19.61%
31.75%
19.22%
Other Income
25.32
29.04
3.04
50.49
87.48
13.88
27.14
34.87
2.58
8.83
12.09
Interest
58.10
56.19
50.17
17.73
16.02
27.16
18.41
3.40
5.23
5.43
3.81
Depreciation
278.48
272.67
275.43
286.78
183.47
157.32
115.23
105.46
82.97
72.21
44.41
PBT
704.13
632.80
385.50
620.12
1,368.08
1,043.47
749.32
541.27
529.09
936.30
359.07
Tax
58.53
16.01
12.60
104.46
253.32
199.18
156.75
120.36
122.19
216.12
76.35
Tax Rate
8.31%
2.53%
3.27%
16.85%
18.52%
19.92%
20.92%
22.24%
23.09%
23.08%
21.26%
PAT
645.60
615.82
341.99
520.94
1,114.76
828.76
593.65
420.72
406.99
720.18
282.72
PAT before Minority Interest
646.04
615.82
341.99
520.94
1,114.76
800.64
592.57
420.91
406.90
720.18
282.72
Minority Interest
0.44
0.00
0.00
0.00
0.00
28.12
1.08
-0.19
0.09
0.00
0.00
PAT Margin
10.16%
9.89%
6.05%
9.82%
20.67%
17.99%
15.09%
13.44%
12.98%
22.75%
13.75%
PAT Growth
16.48%
80.07%
-34.35%
-53.27%
34.51%
39.60%
41.10%
3.37%
-43.49%
154.73%
 
EPS
32.84
31.32
17.40
26.50
56.70
42.15
30.20
21.40
20.70
36.63
14.38

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
4,818.20
4,370.47
5,237.54
5,066.98
3,219.42
2,718.83
2,220.14
1,902.33
1,597.36
884.64
Share Capital
39.31
39.31
39.31
39.31
37.70
37.70
37.70
37.70
37.70
37.70
Total Reserves
4,778.89
4,331.16
5,198.23
5,027.67
3,181.72
2,681.13
2,182.44
1,864.63
1,559.66
846.94
Non-Current Liabilities
2.75
52.42
162.07
361.16
1,046.98
570.06
576.20
94.15
84.02
72.44
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
18.80
Unsecured Loans
0.00
0.00
0.00
199.89
886.99
499.30
500.00
0.00
0.00
0.00
Long Term Provisions
109.51
106.20
95.82
85.52
74.51
52.03
40.76
57.22
28.23
9.36
Current Liabilities
1,520.28
1,640.80
1,830.59
1,533.26
1,751.61
1,663.65
1,267.18
813.96
944.19
684.09
Trade Payables
735.64
679.81
706.39
668.78
625.93
644.34
759.32
500.73
565.65
324.94
Other Current Liabilities
223.66
251.19
516.51
557.92
226.98
380.19
142.89
81.28
51.80
44.56
Short Term Borrowings
430.45
635.87
430.00
0.02
860.50
429.13
207.78
88.51
113.71
219.70
Short Term Provisions
130.53
73.93
177.69
306.54
38.20
209.99
157.19
143.44
213.03
94.88
Total Liabilities
6,341.23
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
1,641.17
Net Block
2,546.71
2,398.45
1,797.85
1,788.42
1,551.84
1,158.45
993.38
799.40
708.09
546.87
Gross Block
3,875.21
3,467.50
2,840.33
2,545.39
2,132.41
1,522.57
1,242.47
950.09
1,093.63
861.06
Accumulated Depreciation
1,328.50
1,069.05
1,042.48
756.97
580.57
364.12
249.09
150.69
385.54
314.19
Non Current Assets
3,197.39
3,149.80
4,255.37
4,056.96
3,526.30
2,820.02
2,116.31
1,316.80
917.30
750.43
Capital Work in Progress
524.36
601.28
2,304.24
2,182.53
1,846.18
1,551.23
1,010.15
396.28
92.52
83.14
Non Current Investment
93.02
96.33
118.40
49.31
17.62
48.76
41.64
49.88
53.43
2.26
Long Term Loans & Adv.
33.30
53.74
34.88
36.70
110.66
61.58
71.14
71.24
29.96
118.15
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
33.30
0.00
Current Assets
3,143.84
2,913.89
2,974.83
2,904.44
2,462.75
2,131.73
1,947.52
1,493.75
1,708.27
890.74
Current Investments
0.00
0.00
0.00
186.97
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,643.54
1,475.27
1,609.70
1,486.15
1,187.54
967.27
733.93
632.75
569.79
382.77
Sundry Debtors
1,024.84
1,046.41
807.13
348.60
864.75
488.92
526.34
338.82
350.48
361.17
Cash & Bank
126.57
82.27
69.43
105.84
80.75
205.62
89.92
159.60
450.83
26.83
Other Current Assets
348.89
55.32
51.65
78.67
329.71
469.92
597.33
362.58
337.17
119.98
Short Term Loans & Adv.
289.03
254.62
436.92
698.21
301.61
451.71
569.84
355.02
330.08
119.98
Net Current Assets
1,623.56
1,273.09
1,144.24
1,371.18
711.14
468.08
680.34
679.79
764.08
206.65
Total Assets
6,341.23
6,063.69
7,230.20
6,961.40
5,989.05
4,951.75
4,063.83
2,810.55
2,625.57
1,641.17

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
803.21
723.94
552.35
1,463.38
449.15
811.97
312.42
328.55
947.65
171.76
PBT
631.83
354.59
625.39
1,368.08
999.82
749.32
541.27
529.09
936.31
359.07
Adjustment
286.86
487.61
417.75
102.42
278.28
117.57
87.12
83.06
69.45
44.61
Changes in Working Capital
-95.63
-57.56
-367.36
238.30
-592.84
111.56
-180.85
-165.64
138.90
-162.50
Cash after chg. in Working capital
823.06
784.64
675.78
1,708.80
685.26
978.45
447.54
446.51
1,144.66
241.18
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-19.85
-60.70
-123.43
-245.42
-236.11
-166.48
-135.12
-117.96
-197.01
-69.42
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-320.61
-447.59
-371.97
-838.80
-731.63
-755.60
-884.38
-485.91
-306.80
-255.61
Net Fixed Assets
-340.94
994.77
-402.51
-1,303.18
-789.71
-638.70
-606.86
-121.60
-288.80
-200.26
Net Investments
2.59
-9.91
123.73
490.16
-326.86
-207.50
-195.85
-65.58
-4.13
0.00
Others
17.74
-1,432.45
-93.19
-25.78
384.94
90.60
-81.67
-298.73
-13.87
-55.35
Cash from Financing Activity
-437.87
-261.96
-217.35
-597.42
154.85
59.03
502.63
-128.88
-224.30
86.72
Net Cash Inflow / Outflow
44.73
14.39
-36.97
27.16
-127.63
115.40
-69.33
-286.24
416.55
2.86
Opening Cash & Equivalents
75.48
61.09
98.06
71.83
199.06
83.74
153.07
439.32
22.77
23.96
Closing Cash & Equivalent
120.21
75.48
61.09
98.06
71.84
199.07
83.74
153.08
439.32
26.83

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
245.14
222.36
266.47
257.80
170.79
144.24
117.78
100.92
84.74
46.93
ROA
9.93%
5.15%
7.34%
17.22%
14.64%
13.15%
12.25%
14.97%
33.76%
18.76%
ROE
13.40%
7.12%
10.11%
26.91%
26.97%
24.00%
20.42%
23.25%
58.03%
36.24%
ROCE
13.42%
7.44%
11.25%
26.28%
23.30%
22.66%
22.15%
28.87%
65.87%
37.54%
Fixed Asset Turnover
1.70
1.79
1.97
2.31
2.52
2.85
2.86
3.07
3.24
2.71
Receivable days
60.69
59.84
39.75
41.06
53.64
47.09
50.43
40.13
41.02
55.91
Inventory Days
91.38
99.60
106.49
90.48
85.38
78.91
79.67
70.01
54.91
61.11
Payable days
150.62
148.04
173.51
187.92
69.87
88.23
98.47
84.03
80.04
69.83
Cash Conversion Cycle
1.45
11.40
-27.27
-56.39
69.15
37.76
31.63
26.12
15.89
47.19
Total Debt/Equity
0.09
0.15
0.12
0.10
0.54
0.42
0.32
0.05
0.07
0.30
Interest Cover
12.24
8.07
36.27
86.40
37.81
41.70
160.20
102.16
173.43
95.30

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Alembic Pharmaceuticals gets USFDA’s final approval for Divalproex Sodium Delayed-Release Capsules
    20th Dec 2024, 17:42 PM

    The company has a cumulative total of 220 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals completes ANVISA GMP audit for API-II Facility in Panelav
    11th Dec 2024, 15:13 PM

    The inspection was conducted from September 16, 2024 to September 20, 2024

    Read More
  • Alembic Pharma gets USFDA’s tentative nod for Olopatadine Hydrochloride Ophthalmic Solution
    4th Dec 2024, 15:59 PM

    The company has a cumulative total of 219 ANDA approvals (192 final approvals and 27 tentative approvals) from USFDA

    Read More
  • USFDA completes inspection at Alembic Pharmaceuticals’ Solid Oral Formulation Facility
    25th Nov 2024, 09:42 AM

    The USFDA issued a Form 483 with five procedural observations

    Read More
  • Alembic Pharma gets USFDA’s final approval for Ivabradine Tablets
    12th Nov 2024, 16:00 PM

    The company has a cumulative total of 218 ANDA approvals from USFDA

    Read More
  • Alembic Pharma gets final nod for Diltiazem Hydrochloride Extended-Release Capsules
    11th Nov 2024, 09:17 AM

    Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of $105.3 million for twelve months ending June 2024 according to IQVIA

    Read More
  • Alembic Pharma gets USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules
    21st Oct 2024, 09:30 AM

    Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension

    Read More
  • USFDA completes inspection at Alembic Pharmaceuticals’ Oncology formulation facility
    9th Oct 2024, 09:50 AM

    The inspection was successfully completed without any Form 483 observation

    Read More
  • Alembic Pharmaceuticals gets final nod for Alcaftadine Ophthalmic Solution
    4th Oct 2024, 09:49 AM

    Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final approval for Lamotrigine Extended-Release Tablets
    3rd Oct 2024, 09:30 AM

    Alembic has a cumulative total of 216 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals gets EIR from USFDA for Oral Solid Formulation Facility
    28th Sep 2024, 10:31 AM

    With this, for all the company’s USFDA facilities, EIRs are in place

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final approval for Paliperidone Extended-Release tablets
    27th Sep 2024, 15:27 PM

    The company has a cumulative total of 215 ANDA approvals (187 final approvals and 28 tentative approvals) from USFDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.